

AMYPOPHARMA S.r.l.

SPIN OFF DELL'UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA

WWW.AMYPOPHARMA.COM

PRESENTATION

AMYPOPHARMA S.r.l. is an Italian biotech start-up company, with the mission to develop **functionalized nanoliposomes for new therapeutic approaches to treat protein misfolding disorders**.

Protein misfolding disorders, known as amyloidoses, are a group of diseases resulting from abnormal deposition of misfolded proteins (amyloids) in different parts of the body, which ultimately results in progressive organ dysfunction in disorders such as **Alzheimer's disease** and other diseases which currently lack effective therapies.

AMYPOPHARMA S.r.l. is a spin-off of Università degli Studi di Milano-Bicocca (Unimib) and was founded in 2015 by Professor Massimo Ernesto Masserini and Doctor Francesca Re.

Research activities are based on the scientific work on **nanoliposome technology** originated from the team lead by the two founders at Unimib.

PRODUCTS & SERVICES

AMYPOPHARMA S.r.l. offers the following products and service:

- Research and development;
- Nanoparticles for the treatment of several severe diseases with unmet medical needs.

Team

Maria Gabriella Camboni
Massimo Ernesto Masserini
Francesca Re
Marco Sardina

Sector

Life Science & Biotechnology

Support

In 2018, **BiovelocITA** has invested in **AMYPOPHARMA** with the objective to accelerate the development of nanoparticles for the treatment of several severe diseases with unmet medical needs.

Contact

Mail: info@amypharma.com
Telephone: +39 02 83991350
Address: Via Gioberti 8, 20123,
Milan, Italy.

